Table 1 Demographics and baseline characteristics
Variable | ABP 501/ABP 501 (N = 230) | RP/ABP 501 (N = 237) | Total* (N = 467)† |
|---|---|---|---|
Women, n (%) | 188 (81.7) | 191 (80.6) | 379 (81.2) |
Age, mean (SD), years | 54.7 (11.71) | 56.1 (11.40) | 55.4 (11.56) |
Ethnicity, n (%) | |||
Hispanic or Latino | 27 (11.7) | 19 (8.0) | 46 (9.9) |
Not Hispanic or Latino | 202 (87.8) | 217 (91.6) | 419 (89.7) |
Race, n (%) | |||
White | 218 (94.8) | 224 (94.5) | 442 (94.6) |
Black or African American | 8 (3.5) | 12 (5.1) | 20 (4.3) |
Asian | 3 (1.3) | 0 (0.0) | 3 (0.6) |
Other | 1 (0.4) | 1 (0.4) | 2 (0.4) |
Geographic region, n (%) | |||
Eastern Europe | 153 (66.5) | 156 (65.8) | 309 (66.2) |
Western Europe | 12 (5.2) | 19 (8.0) | 31 (6.6) |
North America | 65 (28.3) | 62 (26.2) | 127 (27.2) |
Duration of RA at baseline of Parent Study, mean (SD), (years) | 9.13 (7.873) | 9.46 (8.060) | 9.30 (7.961) |
Duration of RA category at baseline of the parent study, n (%) | |||
≤ 5 years | 90 (39.1) | 79 (33.3) | 169 (36.2) |
≥ 5 years | 140 (60.9) | 158 (66.7) | 298 (63.8) |
Investigator Global Health Assessment at baseline of the OLE study, mean (SD) | 2.5 (1.88) | 2.6 (1.80) | 2.6 (1.84) |
DAS28-CRP at baseline of the OLE study, mean (SD) | 3.40 (1.361) | 3.32 (1.299) | 3.36 (1.329) |
Prior biologic use for RA, n (%) | 60 (26.1) | 69 (29.1) | 129 (27.6) |